← FDA Drug Approvals (Drugs@FDA)

REGADENOSON

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: HIKMA · Approved 2023-02-02

Drug application

FDA Application #

ANDA215827

Application type

Abbreviated New Drug Application (Generic)

Brand name

REGADENOSON

Generic name

REGADENOSON

Active ingredients

REGADENOSON

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

HIKMA

Manufacturer

Hikma Pharmaceuticals USA Inc.

First approval

2023-02-02

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown